Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure
NCT02973620 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2018-05-16
Summary
Open label study of levosimendan; planned comparison for effectiveness and safety to historic matched case controls from participating sites.
Conditions
- Heart Decompensation
Interventions
- DRUG
-
Levosimendan
levosimendan infusion started at 0.1 mcg/kg/min for 6-12 hours, increased to 0.2 mcg/kg/min for 24-36 hours
Sponsors & Collaborators
-
Tenax Therapeutics, Inc.
lead INDUSTRY
Eligibility
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Levosimendan In Ambulatory Heart Failure Patients
NCT04705337 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients.
NCT00219388 ·Status: COMPLETED ·Phase: PHASE4
-
Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET)
NCT02261948 ·Status: COMPLETED ·Phase: PHASE4
-
Levosimendan Pharmacokinetics in Children
NCT01704131 ·Status: UNKNOWN
-
Levosimendan for Cardiac Patients Undergoing Major Abdominal Cancer Surgeries
NCT03557255 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetic Modelling of Levosimendan in Adults
NCT06993584 ·Status: NOT_YET_RECRUITING
-
Effect of Levosimendan or Placebo on Exercise in Advanced Chronic Heart Failure
NCT03576677 ·Status: UNKNOWN ·Phase: PHASE4
-
Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction.
NCT00324766 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.
NCT00048425 ·Status: COMPLETED ·Phase: PHASE3
-
Levosimendan Infusion in Critically Ill Patients With Cardiogenic Shock
NCT04917497 ·Status: COMPLETED
-
Inotropic Treatment With Levosimendan (SimdaxR)in Heart Surgery
NCT01221116 ·Status: TERMINATED ·Phase: NA
-
Preoperative Levosimendan and Heart Failure
NCT01022983 ·Status: WITHDRAWN ·Phase: PHASE4
-
Efficacy and Safety of Pulsed Infusions of Levosimendan in Outpatients With Advanced Heart Failure
NCT01065194 ·Status: UNKNOWN ·Phase: PHASE3
-
Myocardial Hemodynamic Effects of Levosimendan
NCT00585104 ·Status: COMPLETED ·Phase: PHASE2
-
Peroral Levosimendan in Chronic Heart Failure
NCT00130884 ·Status: COMPLETED ·Phase: PHASE2
-
Levosimendan Versus Dobutamine for Renal Function in Heart Failure
NCT02133105 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Levosimendan on miRNAs Regulation in the Failing Hearts
NCT04950569 ·Status: UNKNOWN ·Phase: PHASE4
-
A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
NCT06149104 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Prediction of Milrinone or Levosimendan as Initial Inotropic Drug Therapy in Patients With Acute and Advanced Heart Failure With Renal Insufficiency
NCT06205758 ·Status: RECRUITING
-
Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction
NCT02468232 ·Status: COMPLETED ·Phase: PHASE3
-
The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity
NCT06478667 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients
NCT01922089 ·Status: COMPLETED ·Phase: PHASE2
-
Early Management Strategies of Acute Heart Failure for Patients With NSTEMI
NCT03189901 ·Status: UNKNOWN ·Phase: PHASE4
-
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure
NCT02678312 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07192952 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3